University of Bristol

The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.

The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.

The firm's CEO said it is exploring several different disease classes with technology sensitive enough to detect the faint chemical signature of chronic diseases.